Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468929 | 0.90 | TNKS (0.33) | PRLHR | |
| SCHEMBL15241809 | 0.85 | HDAC6 (0.38) | — | |
| SCHEMBL436071 | 0.79 | PRLHR (0.62) | PRLHR | |
| SCHEMBL3716509 | 0.78 | PRLHR (0.51) | PRLHR | |
| SCHEMBL434454 | 0.77 | PRLHR (0.64) | PRLHR | |
| SCHEMBL3713572 | 0.77 | PRLHR (0.49) | PRLHR | |
| SCHEMBL436152 | 0.77 | PRLHR (0.64) | PRLHR | |
| SCHEMBL436151 | 0.77 | PRLHR (0.64) | PRLHR | |
| SCHEMBL434425 | 0.77 | PRLHR (0.64) | PRLHR | |
| SCHEMBL3721666 | 0.76 | PRLHR (0.49) | PRLHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8143026-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120046221-A1 | ALBUMIN FUSION PROTEINS | ROSEN CRAIG A (US) | 2012-02-23 | — | — | US | disclosed |
| US-8106165-B2 | Antibodies to HNFIP24 polypeptides | HUMAN GENOME SCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20120021985-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2311872-A1 | Albumin fusion proteins | Human Genome Sciences, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2298355-A2 | Albumin fusion proteins | Human Genome Sciences, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295456-A1 | Albumin fusion proteins | Human Genome Sciences, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2277889-A2 | Fusion proteins of albumin and interferon beta | Human Genome Sciences, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277888-A2 | Fusion proteins of albumin and erythropoietin | Human Genome Sciences, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277910-A1 | Albumin fusion proteins | Human Genome Sciences, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2275557-A1 | Albumin fusion proteins | Human Genome Sciences, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009312-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110002888-A1 | Albumin Fusion Proteins | HUMAN GEMONE SCIENCES, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003383-A1 | ANTIBODIES TO HT5GJ57 | HUMAN GENOME SCIENCES, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021985-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | PRLHR 3825/4885 |
| US-20110003383-A1 | ANTIBODIES TO HT5GJ57 | TMEM205, SPAG5, HDGFL3 | PRLHR 1206/4885 |
| US-20110002888-A1 | Albumin Fusion Proteins | ALB, FABP1, HDGF | PRLHR 3825/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | PRLHR 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.